BWAY News

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights